Stock listing

NASDAQ:MLTX MoonLake Immunotherapeutics Stock

Home listing (NASDAQ) of MoonLake Immunotherapeutics

Follow MoonLake Immunotherapeutics into a list and get an email when it puts out news.

Share price · NASDAQ:MLTX

$11.07 USD +0.28 (+2.6%)

Close on Nov 20, 2026

Past year -14.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$10.73 – $11.30 USDNov 20, 2026
Volume
1.72M sharesNov 20, 2026
Market cap
$942.1M USDAt the close on Nov 20, 2026 · price × 85.11M shares outstanding
52-week range
$9.46 – $23.29 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$20.06M USDMedian day 1.38M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
MoonLake Immunotherapeutics logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MLTX · Home$11.07 USD+0.28 (+2.6%)1,723,798$10.79$11.30$10.73$10.79Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MLTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$11.07+0.28+2.6%$10.79$11.30$10.731,723,798
$10.79-0.46-4.1%$11.18$11.29$10.781,323,543
$11.25-0.48-4.1%$11.72$11.80$10.941,165,404
$11.73-0.77-6.2%$12.48$12.78$11.641,382,031
$12.50-0.37-2.9%$12.86$13.11$12.401,184,173
$12.87-0.64-4.7%$13.47$13.47$12.871,496,881
$13.51+0.95+7.6%$12.58$13.90$12.511,932,610
$12.56-0.06-0.5%$12.48$13.04$12.30909,175
$12.62+1.09+9.5%$11.68$12.91$11.591,579,405
$11.53+0.73+6.8%$11.14$11.55$11.011,033,607
$10.80-0.76-6.6%$11.11$11.61$10.671,321,209
$11.56-0.14-1.2%$11.86$11.93$10.951,206,429
$11.70+0.23+2.0%$11.52$11.72$11.29845,529
$11.47-0.31-2.6%$11.80$12.00$11.17946,978
$11.78-0.79-6.3%$12.44$12.63$11.711,115,499
$12.57+0.26+2.1%$12.36$12.93$12.314,094,074
$12.31+0.38+3.2%$11.87$12.38$11.711,196,553
$11.93+0.12+1.0%$11.77$12.10$11.54933,730
$11.81-0.04-0.3%$11.82$12.45$11.671,511,233
$11.85-0.49-4.0%$12.07$12.28$11.481,935,000
$12.34+1.69+15.9%$10.70$13.33$10.656,116,200
$10.65+0.33+3.2%$10.34$10.73$10.341,163,600
$10.32+0.57+5.8%$9.77$10.48$9.7311,237,700
$9.75+0.20+2.1%$9.57$9.863$9.50911,600
$9.55-0.71-6.9%$10.34$10.34$9.461,380,800
$10.26+0.12+1.2%$10.16$10.51$10.141,067,200
$10.14-0.27-2.6%$10.30$10.65$10.011,772,800
$10.41-0.27-2.5%$10.70$10.84$10.362,412,500
$10.68-0.14-1.3%$10.82$11.00$10.661,206,900
$10.82+0.24+2.3%$10.58$11.09$10.402,011,000
$10.58-0.19-1.8%$10.75$10.80$10.003,717,300
$10.77-0.18-1.6%$10.81$11.29$10.711,396,000
$10.95-0.43-3.8%$11.50$11.50$10.913,051,100
$11.38-0.03-0.3%$11.56$11.72$11.191,867,200
$11.41-0.06-0.5%$11.64$11.65$11.031,827,800
$11.47-0.23-2.0%$11.73$11.84$11.291,305,100
$11.70+0.25+2.2%$11.52$12.00$11.391,994,400
$11.45-0.11-1.0%$11.56$11.70$11.401,506,800
$11.56-0.48-4.0%$12.04$12.04$11.531,656,900
$12.04-0.08-0.7%$12.15$12.21$11.802,179,500
$12.12-0.78-6.0%$12.69$12.83$12.041,901,500
$12.90-0.48-3.6%$13.41$13.69$12.232,003,200
$13.38+0.83+6.6%$12.73$13.44$12.542,362,000
$12.55+0.16+1.3%$12.50$12.65$12.241,219,800
$12.39+0.04+0.3%$12.28$12.50$12.091,803,100
$12.35-0.11-0.9%$12.66$12.80$12.202,298,100
$12.46+0.26+2.1%$12.29$12.51$11.882,599,700
$12.20-0.48-3.8%$12.70$12.70$12.021,797,600
$12.68+0.17+1.4%$12.56$13.00$12.222,331,800
$12.51-0.67-5.1%$13.33$13.55$12.472,384,200
$13.18-0.54-3.9%$13.58$13.62$13.121,221,600
$13.72-1.22-8.2%$14.90$15.00$13.661,690,100
$14.94-0.07-0.5%$14.80$15.43$14.691,464,800
$15.01-0.18-1.2%$15.06$15.24$14.871,428,200
$15.19+0.13+0.9%$15.08$15.45$14.98841,900
$15.06-0.07-0.5%$15.14$15.47$14.851,187,100
$15.13+0.08+0.5%$14.99$15.31$14.83662,500
$15.05+0.06+0.4%$14.94$15.11$14.631,017,700
$14.99-0.54-3.5%$15.60$15.77$14.97699,900
$15.53-0.09-0.6%$15.62$15.78$15.471,099,500
$15.62+0.06+0.4%$15.50$15.77$15.341,000,300
$15.56+0.19+1.2%$15.54$15.97$15.53819,000
$15.37-0.39-2.5%$15.68$15.69$15.231,138,100
$15.76-0.11-0.7%$15.99$16.10$15.581,350,900
$15.87-0.87-5.2%$16.53$16.74$15.551,367,700
Ticker
NASDAQ:MLTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All MoonLake Immunotherapeutics news

MoonLake Immunotherapeutics on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 55 in all · newest Nov 4, 2026 · oldest 2021
Calls
1 call with a replay · 1 with a transcript · latest Mar 10, 2024
Decks
12 decks · latest Jun 22, 2026

Where MoonLake Immunotherapeutics is listed

ListingExchangeCountryCurrency
NASDAQ:MLTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:MLTXBOATSUnited StatesUSD
BIVA:MLTXNBIVAMexicoMXN
BMV:MLTXNBMVMexicoMXN

Valuation

Price/book 2.5× against a median of 2.4×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$543.7M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.3×
Beta vs S&P 500
1.32

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
MoonLake Immunotherapeutics · NASDAQ:MLTXUS$942.1MUS$543.7Mn/an/an/a2.5×n/a0.3×1.32
Omeros Corporation · NASDAQ:OMERUS$983.7MUS$920.3M10.0×12.4×n/an/a132.3%n/a1.64
Everest Medicines Ltd. · HKEX:1952US$981.6MUS$1.00Bn/a2.8×183×1.3×−2.2%0.4×n/a
HBM Holdings Ltd. · HKEX:2142US$981.4MUS$711.6M10.7×4.5×8.6×2.4×57.8%0.2×n/a
Peptron, Inc. · KRX:087010US$979.2MUS$942.2Mn/a211×n/a10.2×−342.2%0.2×n/a
City Therapeutics, Inc. · NASDAQ:CTYUS$972.4MUS$802.8Mn/a59.2×n/an/a−431.4%n/an/a
Seaport Therapeutics, Inc. · NASDAQ:SPTXUS$966.2MUS$675.8Mn/an/an/a2.4×n/a0.0×0.72
Savara, Inc. · NASDAQ:SVRAUS$939.9MUS$840.4Mn/an/an/a8.7×n/a0.3×1.42
Metis TechBio Co., Ltd. Class H · HKEX:7666US$918.2MUS$486.7Mn/a222×n/a2.0×−373.2%0.0×n/a
InventisBio, Co., Ltd. Class A · SSE:688382US$899.5MUS$714.3Mn/a67.0×n/a4.6×−533.7%0.0×n/a
InnoCare Pharma Ltd. Class A · SSE:688428US$896.7M−US$209.5M9.3×−0.6×−2.3×0.8×27.1%0.1×n/a
Median of the othersUS$969.3MUS$758.5M10.0×35.8×8.6×2.4×−172.2%0.2×1.42

Forecasts

11 strong buy · 1 buy · 2 hold · 2 strong sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
30.29 USD · Analysts' mean
EPS, year to Dec 2026
-3.58 · 8 analysts

Team and board

Officers

OfficerRole
Jorge Santos da SilvaChairman & Chief Executive Officer, Founder

Board

DirectorRole
Catherine MoukheibirChairperson
Jorge Santos da SilvaChairman & Chief Executive Officer, Founder
Andrew J. PhillipsMember
Ramnik XavierDirector
Spike LoyLead Independent Director

Events

Calls

CallWhenStatus
MoonLake Immunotherapeutics (NASDAQ:MLTX) Q4 2023 Earnings CallSun, Mar 10, 2024 · 12:00 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open−1.2%
Q2 2026Aug 10, 2026 · Before open−5.1%
Q1 2026May 11, 2026 · Before open+10.4%
Q4 2025Feb 26, 2026−3.9%
Q3 2025Nov 5, 2025 · Before open+4.5%
Q2 2025Aug 5, 2025 · Before open+0.2%
Q1 2025May 5, 2025 · Before open−1.0%
Q4 2024Feb 26, 2025 · Before open+4.0%
Q3 2024Nov 7, 2024 · Before open−1.6%
Q2 2024Aug 7, 2024 · Before open−2.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open−1.9%
Q4 2023Feb 29, 2024 · Before open−15.1%
Q3 2023Nov 14, 2023 · Before open+2.0%
Q2 2023Aug 10, 2023 · Before open+0.6%
Q1 2023May 12, 2023 · Before open+3.8%
Q4 2022Mar 20, 2023 · Before open−7.9%
Q3 2022Nov 14, 2022 · Before open+0.2%
Q2 2022Aug 12, 2022 · After close+19.4%
Q1 2022May 16, 2022 · After close+1.5%
Q4 2021Feb 17, 2022 · After close0.0%

Open Events

Decks

DeckKindSlidesDate
Investor Day (June 2026)Investor day43 slidesJun 22, 2026
Investor Day (February 2026)Investor day49 slidesFeb 23, 2026
Technical Presentation (2026)Technical17 slides2026
SHSA 2025 (Symposium on Hidradenitis Suppurativa Advances)Conference19 slidesOctober 2025
Investor Day (March 2024)Investor day102 slidesMar 11, 2024
Technical Presentation (November 2023)Technical42 slidesNov 6, 2023
Investor Day (September 2023)Investor day71 slidesSep 11, 2023
Investor Day (June 2023)Investor day38 slidesJun 26, 2023
Investor Day (April 2023)Investor day85 slidesApr 19, 2023
Investor Day (June 2022)Investor day77 slidesJun 7, 2022
All 12 decks
DeckKindSlidesDate
Helix Acquisition — SPAC Merger (January 2022)SPAC merger33 slidesJan 19, 2022
Helix Acquisition — SPAC Merger (October 2021)SPAC merger33 slidesOct 4, 2021

Open Decks

Financings

RaiseDate
Public offering of class A ordinary shares and pre-funded warrants
Made bigger: about US$200M · US$20 a share · Leerink Partners +5
Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), LifeSci Capital (co-lead), H.C. Wainwright & Co., Clear Street
Use of proceeds: Research, development, pre-commercialization and commercialization of sonelokimab, if approved, and general corporate purposes
Jun 24, 2026
Public offering of class A ordinary shares
Announced: about US$75M · US$10.5 a share · Leerink Partners
Dealers: Leerink Partners (lead)
Use of proceeds: To fund research and development of sonelokimab and for general corporate purposes
Nov 5, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Helix Acquisition Corp, a blank check company (SPAC). Priced at US$10.00 a share on Oct 19, 2020.

Price
US$10.00 a share
Shares offered
10,000,000 Class A ordinary shares
Offering size
US$100 million
Underwriters' option
Up to 1,500,000 more shares
Listing
HLXA on the Nasdaq Capital Market
Underwriter
Jefferies
Shares delivered
On or about Oct 22, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceAug 28, 2020
Filed publiclyOct 1, 2020
Amended twiceNewest Oct 16, 2020
Shares registered with an exchangeOct 19, 2020
Declared effective by the SECOct 19, 2020
Final prospectus, with the priceOct 21, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 21, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue0000
Cost of revenue2.62M1.38M13.2K12.4K4.97K
Gross profit-2.62M-1.38M-13.2K-12.4K-4.97K
Research and development202.9M112.8M31.8M42.0M35.5M
Selling, general and administrative42.0M30.3M22.3M23.0M4.57M
Operating income-244.8M-143.1M-54.1M-65.1M-4.57M-105.8K
Depreciation and amortization2.62M1.39M370.0K164.8K4.97K206.3K
EBITDA-242.2M-141.7M-53.8M-64.9M-4.57M100.5K
Interest expense7.25M00591.7K0
Income before tax-229.7M-121.0M-44.0M-64.5M-4.54M-90.8K
Income tax611.0K282.0K94.0K36.4K5.71K-206.3K
Net income-227.3M-118.9M-36.0M-50.0M-4.54M-90.8K
Earnings per share, basic-3.53-1.89-0.73-1.70-0.31-0.01
Earnings per share, diluted-3.53-1.89-0.73-1.70-0.31

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents334.5M180.4M451.2M39.5M8.04M1.34M
Short-term investments59.5M267.6M59.8M32.6M0
Receivables4.87M2.84M1.06M217.1K148.8K
Inventory1.32M
Current assets421.7M474.3M514.2M76.5M9.64M1.62M
Property, plant and equipment577.0K722.0K320.9K49.4K45.7K
Total assets424.4M477.9M526.5M76.8M9.68M116.6M
Accounts payable28.4M8.68M1.46M47.5K1.23M
Current liabilities45.5M22.5M9.97M7.67M21.1M125.2K
Long-term debt74.1M
Total debt74.1M03.70M282.6K15.0M58.1K
Total liabilities120.0M24.5M13.0M8.08M21.3M4.15M
Shareholders' equity304.5M446.8M495.7M48.9M-11.6M112.5M
Shares outstanding85.1M62.9M49.1M29.4M36.9M14.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-196.0M-116.6M-42.8M-55.9M-611.1K-316.7K
Capital spending-35.0K-520.0K-284.0K-16.0K-50.7K0
Free cash flow-196.0M-117.1M-43.1M-55.9M-35.2M-316.7K
Cash from investing203.0M-205.6M-25.2M-32.3M-50.7K-115.0M
Cash from financing146.0M51.3M479.7M119.7M-58.1K116.7M
Dividends paid-51.9K
Share buybacks-5000-6.20K
Change in cash154.1M-270.7M411.7M31.5M-669.1K1.34M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
8-K · Current reportSep 30, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 10, 2026Offer documentSEC
S-3ASR · Registration statementAug 10, 2026Offer documentSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
8-K · Current reportJul 14, 2026Current reportSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 29, 2026Big-stake noticeSEC
8-K · Current reportJun 25, 2026Material contractSEC
424B5 · ProspectusJun 24, 2026Offer documentSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
424B5 · ProspectusJun 22, 2026Offer documentSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 22, 2026Current reportSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
8-K · Current reportJun 9, 2026Management or board changeSEC
8-K · Current reportJun 1, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
ARS · Annual report to shareholdersApr 21, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2026Meeting noticeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 14, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
144 · Notice of proposed saleApr 10, 2026Other filingsSEC
144 · Notice of proposed saleApr 9, 2026Other filingsSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 2, 2026Big-stake noticeSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
10-K · Annual reportFeb 25, 2026Annual reportSEC
8-K · Current reportFeb 23, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026Current reportSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 10, 2025Big-stake noticeSEC
8-K · Current reportNov 5, 2025Material contractSEC
424B5 · ProspectusNov 5, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 1, 2025Big-stake noticeSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
8-K · Current reportSep 29, 2025Current reportSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
144 · Notice of proposed saleJul 3, 2025Other filingsSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
8-K · Current reportApr 29, 2025Current reportSEC
ARS · Annual report to shareholdersApr 22, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2025Meeting noticeSEC
8-K · Current reportApr 3, 2025Material contractSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
10-K · Annual reportFeb 26, 2025Annual reportSEC
8-K · Current reportFeb 26, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
8-K · Current reportDec 18, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedOct 8, 2024Big-stake noticeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
8-K · Current reportSep 11, 2024Current reportSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportAug 7, 2024ResultsSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
8-K · Current reportJun 10, 2024Current reportSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 6, 2024Meeting outcomeSEC
UPLOAD · Letter from the SECMay 13, 2024Other filingsSEC
CORRESP · Letter to the SECMay 7, 2024Other filingsSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
10-K/A · Annual report, amendedMay 7, 2024Annual reportSEC
UPLOAD · Letter from the SECApr 29, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 24, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2024Meeting noticeSEC
8-K · Current reportMar 11, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedMar 5, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 29, 2024Insider tradeSEC
4 · Change in ownershipFeb 29, 2024Insider tradeSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC
8-K · Current reportFeb 29, 2024ResultsSEC
8-K · Current reportFeb 26, 2024Current reportSEC
4 · Change in ownershipFeb 23, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
144 · Notice of proposed saleFeb 15, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 15, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
144 · Notice of proposed saleFeb 14, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipDec 21, 2023Insider tradeSEC
144 · Notice of proposed saleDec 20, 2023Other filingsSEC
144 · Notice of proposed saleDec 19, 2023Other filingsSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
8-K · Current reportNov 6, 2023Current reportSEC
8-K · Current reportOct 16, 2023Current reportSEC
4 · Change in ownershipOct 10, 2023Insider tradeSEC
4 · Change in ownershipOct 4, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 12, 2023Other filingsSEC
8-K · Current reportSep 11, 2023Current reportSEC
CORRESP · Letter to the SECSep 7, 2023Other filingsSEC
UPLOAD · Letter from the SECSep 6, 2023Other filingsSEC
8-K · Current reportSep 1, 2023Management or board changeSEC
S-3 · Registration statementAug 31, 2023Offer documentSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJun 30, 2023Big-stake noticeSEC
8-K · Current reportJun 29, 2023Material contractSEC
424B5 · ProspectusJun 29, 2023Offer documentSEC
4 · Change in ownershipJun 28, 2023Insider tradeSEC
424B3 · ProspectusJun 27, 2023Offer documentSEC
424B5 · ProspectusJun 26, 2023Offer documentSEC
8-K · Current reportJun 26, 2023Current reportSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
8-K · Current reportJun 7, 2023Meeting outcomeSEC
8-K · Current reportMay 19, 2023Management or board changeSEC
424B5 · ProspectusMay 11, 2023Offer documentSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
EFFECT · Notice that a registration is effectiveMay 10, 2023Other filingsSEC
CORRESP · Letter to the SECMay 5, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveMay 5, 2023Other filingsSEC
UPLOAD · Letter from the SECMay 4, 2023Other filingsSEC
S-3 · Registration statementMay 1, 2023Offer documentSEC
POS AM · Amendment to an effective registrationMay 1, 2023Offer documentSEC
ARS · Annual report to shareholdersApr 26, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2023Meeting noticeSEC
8-K · Current reportApr 19, 2023Current reportSEC
4 · Change in ownershipApr 7, 2023Insider tradeSEC

This page holds 200 of 331 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from MoonLake Immunotherapeutics’ releases · as of Nov 5, 2025

Common shares
85,106,685
Fully diluted
85,106,685

Fully diluted

LineShares
Common shares85,106,685

Share count over time

CountShares
Nov 22, 202685,106,685

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
T. Rowe Price Capital Appreciation Fund1.61MUS$31.4MJun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.919KUS$17.9MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.792KUS$15.4MJun 30, 2026
JNL/T. Rowe Price Capital Appreciation Fund350KUS$6.82MJun 30, 2026
T. Rowe Price Capital Appreciation Equity ETF168KUS$3.27MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio161KUS$3.1MMay 29, 2026
Vy(R) T. Rowe Price Capital Appreciation Portfolio160KUS$3.12MJun 30, 2026
Select Biotechnology Portfolio144KUS$2.75MMay 31, 2026
Penn Series Flexibly Managed Fund112KUS$2.18MJun 30, 2026
Nomura Healthcare Fund110KUS$2.14MJun 30, 2026
All 50 holders
HolderSharesValueAs of
JNL Multi-Manager Small Cap Value Fund109KUS$2.13MJun 30, 2026
Vanguard Health Care Index Fund94,919US$1.82MMay 31, 2026
Invesco Dorsey Wright SmallCap Momentum ETF80,780US$1.55MMay 31, 2026
ALPS Medical Breakthroughs ETF73,934US$1.42MMay 31, 2026
iShares ESG Aware MSCI USA Small-Cap ETF65,400US$1.25MMay 31, 2026
T. Rowe Price Health Sciences Portfolio55,515US$1.08MJun 30, 2026
Small Cap Value Portfolio50,010US$974KJun 30, 2026
Victory Small Cap Stock Fund45,833US$845KJul 31, 2026
Fidelity Nasdaq Composite Index Fund43,692US$838KMay 31, 2026
Small Cap Equity Fund34,570US$673KJun 30, 2026
Nuveen ESG Small-Cap ETF34,135US$629KJul 31, 2026
Fidelity Nasdaq Composite Index ETF30,712US$589KMay 31, 2026
Optimize Strategy Index ETF24,335US$474KJun 30, 2026
JNL/T. Rowe Price Capital Appreciation Equity Fund23,859US$465KJun 30, 2026
AZL T Rowe Price Capital Appreciation Fund20,914US$407KJun 30, 2026
Fidelity MSCI Health Care Index ETF20,634US$380KJul 31, 2026
Health Sciences Trust17,234US$336KJun 30, 2026
BlackRock Advantage SMID Cap Fund, Inc.17,063US$332KJun 30, 2026
Virtus Biotech Clinical Trials Etf16,630US$307KJul 31, 2026
EQ/T.Rowe Price Health Sciences Portfolio14,014US$273KJun 30, 2026
Small Company Value Trust11,340US$221KJun 30, 2026
Capital Appreciation Value Trust11,317US$220KJun 30, 2026
Clearwater Select Equity Fund10,515US$205KJun 30, 2026
Health Sciences Portfolio9,574US$186KJun 30, 2026
Acuitas US Microcap Fund8,800US$171KJun 30, 2026
T. Rowe Price Health Care ETF7,823US$152KJun 30, 2026
Victory Extended Market Index Fund7,308US$135KJul 31, 2026
Small Cap Core Fund6,816US$133KJun 30, 2026
Blackstone Alternative Multi-Strategy Fund6,300US$123KJun 30, 2026
BlackRock Advantage SMID Cap V.I. Fund4,705US$91,606Jun 30, 2026
Harbor Active Small Cap Growth ETF4,489US$82,777Jul 31, 2026
Capital Appreciation Portfolio3,350US$65,225Jun 30, 2026
JNL/DFA U.S. Small Cap Fund2,307US$44,917Jun 30, 2026
Virtus AlphaSimplex Global Alternatives Fund1,488US$28,971Jun 30, 2026
iShares MSCI World Small-Cap ETF1,428US$27,389May 31, 2026
Total Stock Market Index Trust1,145US$22,293Jun 30, 2026
T. Rowe Price Innovation Leaders ETF861US$16,764Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND301US$5,550Jul 31, 2026
Innovator U.S. Small Cap Managed 10 Buffer ETF274US$5,053Jul 31, 2026
E*TRADE No Fee Total Market Index Fund10US$184Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Reich Kristian
Officer: Chief Scientific Officer
Sale1,100USD 20.00US$22,000Jul 27, 2026
Reich Kristian
Officer: Chief Scientific Officer
Sale2,448USD 20.00US$48,960Jul 22, 2026
Reich Kristian
Officer: Chief Scientific Officer
Sale50,000USD 20.02US$1MJul 21, 2026
Reich Kristian
Officer: Chief Scientific Officer
Sale43,700USD 20.09US$878KJul 20, 2026
Reich Kristian
Officer: Chief Scientific Officer
Sale16,105USD 20.01US$322KJul 15, 2026
Santos da Silva Jorge
Director, Officer: Chief Executive Officer
Sale68,289USD 20.02US$1.37MJul 10, 2026
Santos da Silva Jorge
Director, Officer: Chief Executive Officer
Sale33,936USD 20.01US$679KJul 9, 2026
Santos da Silva Jorge
Director, Officer: Chief Executive Officer
Sale47,775USD 20.03US$957KJul 1, 2026
Bodenstedt Matthias
Officer: Chief Financial Officer
Sale39,120USD 22.04US$862KJun 22, 2026
Bodenstedt Matthias
Officer: Chief Financial Officer
Sale2,794USD 19.60US$54,762Jun 18, 2026
All 23 trades
TradeTradeSharesPriceValueDate
Bodenstedt Matthias
Officer: Chief Financial Officer
Sale15,082USD 19.68US$297KJun 17, 2026
Reich Kristian
Officer: Chief Scientific Officer
Sale50,000USD 19.43US$972KJun 17, 2026
Reich Kristian
Officer: Chief Scientific Officer
Sale50,000USD 18.70US$935KJun 16, 2026
Reich Kristian
Officer: Chief Scientific Officer
Sale50,000USD 18.89US$945KJun 15, 2026
Bodenstedt Matthias
Officer: Chief Financial Officer
Sale13,653USD 20.02US$273KMay 11, 2026
Bodenstedt Matthias
Officer: Chief Financial Officer
Sale2,426USD 19.56US$47,453Apr 14, 2026
Santos da Silva Jorge
Director, Officer: Chief Executive Officer
Sale51,873USD 18.23US$946KApr 13, 2026
Santos da Silva Jorge
Director, Officer: Chief Executive Officer
Sale98,127USD 18.41US$1.81MApr 10, 2026
Bodenstedt Matthias
Officer: Chief Financial Officer
Sale1,925USD 19.51US$37,557Apr 10, 2026
Bodenstedt Matthias
Officer: Chief Financial Officer
Sale85,870USD 18.94US$1.63MApr 9, 2026
Lampert Mark N
Director, 10% owner
Sale1,932,354USD 16.79US$32.4MMar 31, 2026
Lampert Mark N
Director, 10% owner
Sale1,569,116USD 16.79US$26.3MMar 31, 2026
Lampert Mark N
Director, 10% owner
Sale248,530USD 16.79US$4.17MMar 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bihua Chen
Other companies: BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Helix Acquisition Corp. III (Chairperson and CEO, Director · Since at least Jan 22, 2026); BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Feb 8, 2024); Biomea Fusion, Inc. (Director · Since at least Apr 15, 2021); Erasca, Inc. (Director · Jul 15, 2021 – Jun 22, 2023 · Past); Monte Rosa Therapeutics, Inc. (Director · Jun 23, 2021 – Jun 23, 2021 · Past); Verve Therapeutics Inc (Director · Jun 16, 2021 – Jun 21, 2021 · Past); Rain Oncology Inc (Director · Apr 22, 2021 – Apr 27, 2021 · Past); Design Therapeutics, Inc. (Director · Mar 25, 2021 – Mar 25, 2021 · Past); Prometheus Biosciences Inc (Director · Mar 11, 2021 – Mar 11, 2021 · Past); BioAtla, Inc. (Director · Dec 15, 2020 – Dec 18, 2020 · Past); Olema Pharmaceuticals, Inc. (Director · Nov 18, 2020 – Nov 23, 2020 · Past); Atea Pharmaceuticals, Inc. (Director · Oct 29, 2020 – Nov 3, 2020 · Past); Akouos Inc (Director · Jun 25, 2020 – Jun 30, 2020 · Past); Avidity Biosciences, Inc (Director · Jun 11, 2020 – Jun 16, 2020 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Aug 12, 2019 · Past); Axonics Modulation Technologies Inc (Director · Oct 30, 2018 – Oct 31, 2018 · Past); Constellation Pharmaceuticals Inc (Director · Jul 18, 2018 – Jul 18, 2018 · Past); Kezar Life Sciences, Inc. (Director · Jun 20, 2018 – Jun 25, 2018 · Past); Kiniksa Pharmaceuticals International, plc (Director · May 23, 2018 – May 29, 2018 · Past); Apellis Pharmaceuticals, Inc. (Director · Nov 8, 2017 – Nov 13, 2017 · Past); Kineta Inc. (Director · Nov 3, 2016 – Dec 14, 2017 · Past); Clearside Biomedical Inc (Director · Jun 1, 2016 – Jun 1, 2016 · Past); Cellectar Biosciences, Inc. (Director · Aug 15, 2014 – Aug 15, 2014 · Past)
CEO and Chairman, Director · Oct 19, 2020 – Oct 22, 2020 · Past
John Schmid
Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); AnaptysBio, Inc. (Director · Since at least Feb 2, 2018); BridgeBio Oncology Therapeutics, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past)
Director · Oct 19, 2020 – Oct 19, 2020 · Past
Nancy Chang
Other companies: Immix Biopharma, Inc. (Independent Director · Since at least Sep 8, 2025); Galera Therapeutics, Inc. (Director · Since at least Dec 30, 2024); W&T Offshore, Inc. (Director · Since at least Apr 28, 2023); SciClone Pharmaceuticals Inc (Director · Sep 17, 2013 – Oct 13, 2017 · Past); Charles River Laboratories International, Inc. (Director · Oct 24, 2007 – May 7, 2010 · Past); Tanox Inc (Director · Dec 31, 2005 – Nov 2, 2006 · Past)
Director · Oct 19, 2020 – Oct 19, 2020 · Past
Mark N Lampert
Other companies: Immunic, Inc. (Director · Since at least Feb 17, 2026); Kymera Therapeutics, Inc. (Director · Since at least Jan 11, 2023); Olema Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2022); Rain Oncology Inc (Director · Nov 8, 2022 – Jan 25, 2024 · Past); CTi Biopharma Corp (Director · Aug 9, 2022 – Jun 26, 2023 · Past)
Director · Since at least Apr 5, 2022
Andrew J. Phillips
Other companies: OnKure Therapeutics, Inc. (Director · Since at least Oct 4, 2024); Enliven Therapeutics, Inc. (Director · Feb 23, 2023 – Feb 6, 2025 · Past)
Member · Since at least Apr 5, 2022
Catherine Moukheibir
Other companies: Ironwood Pharmaceuticals, Inc. (Director · Since at least Apr 1, 2019)
Chairperson · Since at least Apr 5, 2022
da Silva Jorge SantosChief Executive Officer, Director · Since at least Apr 5, 2022
Jay ScollinsChief Financial Officer · Oct 19, 2020 – Oct 19, 2020 · Past
Jorge Santos da SilvaChairman & Chief Executive Officer, Founder · Since at least Aug 10, 2026
Kara LassenDirector · Apr 5, 2022 – Apr 5, 2022 · Past
All 15 people
PersonSeat
Kristian ReichChief Scientific Officer · Since at least Sep 2, 2025
Matthias BodenstedtChief Financial Officer · Since at least Apr 5, 2022
Ramnik XavierDirector · Since at least Apr 5, 2022
Simon SturgeDirector · Since at least Oct 1, 2023
Spike LoyLead Independent Director · Since at least Apr 5, 2022

Open People

Log in to ask 6ix AI your own questions about MoonLake Immunotherapeutics.